Traders see limited odds of a new COVID variant of concern before 2027 because Omicron-descendant lineages continue to circulate at low levels without triggering the heightened transmissibility, severity, or immune escape thresholds for VOC status under current WHO criteria. As of mid-2026, variants under monitoring such as XFG and BA.3.2 show notable spike mutations and some antibody evasion yet remain constrained by reduced fitness and fail to drive substantial rises in hospitalizations or deaths. High population immunity from prior infections and vaccinations, combined with improved clinical care, keeps overall disease burden stable and low, with global test positivity remaining minimal. Vaccine advisory panels are instead focusing on targeted updates to match dominant strains like XFG for the 2026-2027 season, reflecting routine adaptation rather than crisis-level evolution.